Learn more →
Back to Expert Scholars
clinical / clinicalpancreatic oncology

Takuji Okusaka

奥坂拓志

MD, PhD

🏢National Cancer Center Hospital, Tokyo(日本国立癌症研究中心医院)🌐Japan

Chief, Hepatobiliary and Pancreatic Oncology Division肝胆胰肿瘤科主任

45
h-index
2
Key Papers
2
Awards
3
Key Contributions

👥Biography 个人简介

Takuji Okusaka, MD, PhD is Chief of the Hepatobiliary and Pancreatic Oncology Division at the National Cancer Center Hospital in Tokyo and is Japan's leading clinical investigator in pancreatic and biliary tract cancers. He has led landmark Japanese clinical trials in PDAC, pNETs, and CCA, including studies that established gemcitabine-based regimens and sunitinib in the Japanese population. His work has contributed to global understanding of racial differences in drug metabolism and toxicity profiles for pancreatic and biliary malignancies, and he serves on major JSCO, JSH, and ASCO committees.

Share:

🧪Research Fields 研究领域

Pancreatic Neuroendocrine Tumors胰腺神经内分泌肿瘤
Pancreatic Cancer胰腺癌
Biliary Tract Cancer胆道肿瘤
Gemcitabine Regimens吉西他滨方案
Somatostatin Analogues生长抑素类似物

🎓Key Contributions 主要贡献

pNET Systemic Therapy Trials in Japan

Led pivotal Japanese trials validating sunitinib and everolimus for advanced pancreatic neuroendocrine tumors, confirming efficacy and characterizing distinct toxicity patterns in Asian patients and informing Japanese regulatory approvals.

Gemcitabine-Based Chemotherapy in PDAC

Designed and executed prospective trials optimizing gemcitabine schedules and combinations in Japanese patients with advanced PDAC, contributing to national treatment guidelines adopted by the Japan Pancreas Society.

Biliary Tract Cancer Clinical Research

Led multicenter Japanese trials evaluating gemcitabine/cisplatin and subsequent lines of therapy in biliary tract cancers, providing Asia-specific data integral to international guideline development.

Representative Works 代表性著作

[1]

Phase III Trial of Gemcitabine plus S-1 versus Gemcitabine alone in Patients with Advanced Pancreatic Cancer in Japan

Annals of Oncology (2017)

Demonstrated non-inferiority and improved tolerability of the GS regimen in Japanese PDAC patients, influencing Asian treatment practice.

[2]

Sunitinib for Japanese Patients with Pancreatic Neuroendocrine Tumors: A Phase II Study

Cancer Science (2015)

Validated sunitinib efficacy and characterized dose-modification needs in the Japanese pNET population.

🏆Awards & Recognition 奖项与荣誉

🏆Japanese Society of Medical Oncology Distinguished Service Award 2022
🏆Japan Pancreas Society Excellence in Research Award 2020

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 奥坂拓志 的研究动态

Follow Takuji Okusaka's research updates

留下邮箱,当我们发布与 Takuji Okusaka(National Cancer Center Hospital, Tokyo)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment